Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Concert Pharmaceuticals Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects

NCT05467709
View directory record Official record
Conditions
Health Volunteers
Interventions
Midazolam, CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

NCT03137381
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543, CTP-543 matching placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
13
States / cities
Irvine, California • Rancho Mirage, California • Redwood City, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

NCT04797650
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543 matching placebo, CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
25
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

NCT04784533
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543, Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers

NCT05467696
View directory record Official record
Conditions
Health Volunteers
Interventions
CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543

NCT05467722
View directory record Official record
Conditions
Hepatic Impairment
Interventions
CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

NCT04092712
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543

NCT05468749
View directory record Official record
Conditions
Renal Impairment
Interventions
CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

NCT01487109
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
CTP-499, Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
49
States / cities
Tempe, Arizona • Harrisburg, Arkansas • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects

NCT05478772
View directory record Official record
Conditions
Health Volunteers
Interventions
CTP-543, Fluconazole
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

NCT03941548
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543, CTP-543 Matching Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Centennial, Colorado • Tampa, Florida • Plainfield, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects

NCT04843540
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1 Interventional

Safety & Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney Disease

NCT01460199
View directory record Official record
Conditions
Stage 3 Chronic Kidney Disease
Interventions
CTP-499, placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Costa Mesa, California • Garden Grove, California • Tustin, California
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

NCT03811912
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543, CTP-543 Matching Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
10
States / cities
Irvine, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study of CTP-543 in Healthy Volunteers

NCT03880136
View directory record Official record
Conditions
Healthy
Interventions
CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers

NCT03880253
View directory record Official record
Conditions
Healthy
Interventions
CTP-692
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label Crossover Study Comparing CTP-543 to Jakafi®

NCT02960945
View directory record Official record
Conditions
Healthy
Interventions
CTP-543, 16 mg (2 x 8 mg tablet), Jakafi 15Mg Tablet
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects

NCT04743414
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers

NCT03830463
View directory record Official record
Conditions
Healthy
Interventions
CTP-692, Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)

NCT04518995
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543 matching placebo, CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Bakersfield, California • Encinitas, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers

NCT05192369
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CTP-543, Moxifloxacin, Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia

NCT04158687
View directory record Official record
Conditions
Schizophrenia
Interventions
CTP-692, Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
26
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Cerritos, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

NCT04309643
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CTP-543, Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499

NCT01328821
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
CTP-499
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 25, 2011 · Synced Sep 28, 2026, 10:12 AM EDT